
Symbiox Investment (SYMBIOX) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
4.6M
Gross Profit
2.3M
49.18%
Operating Income
885.0K
19.32%
Net Income
669.0K
14.60%
EPS (Diluted)
₹0.02
Balance Sheet Metrics
Total Assets
319.7M
Total Liabilities
2.4M
Shareholders Equity
317.2M
Debt to Equity
0.01
Cash Flow Metrics
Revenue & Profitability Trend
Symbiox Investment Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 27.6M | 39.0M | 39.8M | 18.3M | 20.8M |
Cost of Goods Sold | 21.1M | 34.7M | 32.3M | 10.9M | 25.3M |
Gross Profit | 6.5M | 4.2M | 7.5M | 7.4M | -4.5M |
Gross Margin % | 23.5% | 10.9% | 18.8% | 40.2% | -21.8% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 512.5K | 665.6K | 1.2M | 1.1M | 335.6K |
Other Operating Expenses | 1.7M | 1.5M | 1.3M | 2.4M | 2.8M |
Total Operating Expenses | 2.2M | 2.1M | 2.5M | 3.5M | 3.1M |
Operating Income | 2.6M | 182.8K | 3.0M | 2.1M | -9.1M |
Operating Margin % | 9.2% | 0.5% | 7.5% | 11.4% | -44.0% |
Non-Operating Items | |||||
Interest Income | 39.0K | 9.7K | 86.0K | 0 | 10.1M |
Interest Expense | 2.3K | 1.8K | 33 | 0 | 1.8K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 2.6M | 2.5M | 2.2M | 1.9M | 937.8K |
Income Tax | 674.2K | 392.6K | 563.8K | 487.9K | 243.8K |
Effective Tax Rate % | 26.0% | 15.9% | 26.2% | 26.0% | 26.0% |
Net Income | 1.9M | 2.1M | 1.6M | 1.4M | 693.9K |
Net Margin % | 6.9% | 5.3% | 4.0% | 7.6% | 3.3% |
Key Metrics | |||||
EBITDA | 2.6M | 2.5M | 3.1M | 2.2M | 939.6K |
EPS (Basic) | ₹0.06 | ₹0.07 | ₹0.51 | ₹0.04 | ₹0.02 |
EPS (Diluted) | ₹0.06 | ₹0.07 | ₹0.51 | ₹0.04 | ₹0.02 |
Basic Shares Outstanding | 31455934 | 31082343 | 31287330 | 31287330 | 31287330 |
Diluted Shares Outstanding | 31455934 | 31082343 | 31287330 | 31287330 | 31287330 |
Income Statement Trend
Symbiox Investment Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 10.6M | 3.1M | 5.4M | 1.9M | 1.5M |
Short-term Investments | 127.1M | 98.8M | 127.2M | 175.4M | 179.4M |
Accounts Receivable | 1.6M | 153.7K | 8.0M | 8.7M | 3.0K |
Inventory | 13.0M | 896.2K | 2.1M | 0 | 0 |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 319.5M | 318.2M | 327.6M | 318.1M | 332.5M |
Non-Current Assets | |||||
Property, Plant & Equipment | 151.6K | 151.6K | 38.0K | 38.0K | - |
Goodwill | 0 | 0 | 0 | 0 | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | - | - | - | - |
Total Non-Current Assets | 151.8K | 180.6K | 37.5K | 37.5K | 37.5K |
Total Assets | 319.7M | 318.4M | 327.6M | 318.1M | 332.5M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 1.5M | 2.0M | 13.3M | 6.0M | 22.0M |
Short-term Debt | - | 0 | 0 | 0 | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 232.0K | 54.0K | 525.0K | -11.0K | 28.5K |
Total Current Liabilities | 2.4M | 3.0M | 14.4M | 6.5M | 22.9M |
Non-Current Liabilities | |||||
Long-term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | - |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2.4M | 3.0M | 14.4M | 6.5M | 22.9M |
Equity | |||||
Common Stock | 312.9M | 312.9M | 312.9M | 312.9M | 312.9M |
Retained Earnings | 3.9M | 2.0M | -71.9K | -1.6M | -3.7M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 317.2M | 315.3M | 313.2M | 311.7M | 309.6M |
Key Metrics | |||||
Total Debt | 0 | 0 | 0 | 0 | 0 |
Working Capital | 317.1M | 315.1M | 313.2M | 311.6M | 309.6M |
Balance Sheet Composition
Symbiox Investment Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 2.6M | 2.5M | 2.2M | 1.9M | 937.8K |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 33.6M | -32.5M | -46.4M | -5.1M | 10.7M |
Operating Cash Flow | 36.2M | -30.0M | -44.2M | -3.3M | 11.6M |
Investing Activities | |||||
Capital Expenditures | 0 | -143.2K | 0 | 0 | 0 |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | 0 | -143.2K | 0 | 0 | 0 |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | 0 | 0 | 0 | 0 | 0 |
Free Cash Flow | 35.8M | -30.7M | -44.7M | -3.5M | 11.4M |
Net Change in Cash | 36.2M | -30.2M | -44.2M | -3.3M | 11.6M |
Cash Flow Trend
Symbiox Investment Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
34.63
Price to Book
0.27
Price to Sales
2.98
PEG Ratio
0.04
Profitability Ratios
Profit Margin
8.70%
Operating Margin
19.32%
Return on Equity
0.60%
Return on Assets
0.60%
Financial Health
Current Ratio
132.00
Debt to Equity
0.00
Beta
-1.22
Per Share Data
EPS (TTM)
₹0.08
Book Value per Share
₹10.14
Revenue per Share
₹0.93
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
symbiox | 86.7M | 34.63 | 0.27 | 0.60% | 8.70% | 0.00 |
KPR Mill | 366.2B | 44.40 | 7.32 | 16.30% | 12.60% | 9.32 |
Trident | 152.5B | 33.75 | 3.31 | 8.00% | 6.27% | 35.39 |
Sanathan Textiles | 42.2B | 27.96 | 2.33 | 8.87% | 5.09% | 59.97 |
Raymond | 40.5B | 93.84 | 1.09 | 183.56% | 271.84% | 17.81 |
Jindal Worldwide | 37.1B | 48.37 | 4.60 | 9.60% | 3.22% | 100.72 |
Financial data is updated regularly. All figures are in the company's reporting currency.